2024-515226-81-00招募中3 期
Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 2,500
- 试验地点
- 25
- 主要终点
- Myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery
研究概览
简要总结
To determine the effect of perioperative administration of ivabradine in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. The primary outcome is myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Undergoing noncardiac surgery
- •≥45 years of age
- •Expected to require at least an overnight hospital stay after surgery
- •Written informed consent to participate in the PREVENT-MINS Trial provided
- •Fulfil ≥1 of the following 5 criteria (A-E): A. Current or prior history of coronary artery disease as defined by any one of the following 7 criteria: i. History of angina; ii. History of acute coronary syndrome; iii. History of a segmental cardiac wall motion abnormality on echocardiography or a segmental fixed defect on radionuclide imaging; iv. History of a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test demonstrating cardiac ischaemia; v. History of a coronary angiographic or CT coronary angiographic evidence of atherosclerotic stenosis ≥50% of the diameter of any coronary artery; vi. ECG with pathological Q waves in at least two contiguous leads; OR vii. Previous coronary artery revascularization, (i.e. percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]);
- •Fulfil ≥1 of the following 5 criteria (A-E): B. Peripheral arterial disease as defined by a physician diagnosis of a current, or prior history of any of the following 4 criteria: i. Intermittent claudication; ii. Vascular surgery OR percutaneous transluminal angioplasty (PTA) for atherosclerotic disease; iii. An ankle/brachial systolic blood pressure ratio <0.90 in either leg at rest; OR iv. Angiographic, CT angiographic or doppler findings demonstrating >70% stenosis in a noncardiac artery;
- •Fulfil ≥1 of the following 5 criteria (A-E): C. History of stroke as defined by any one of the following 2 criteria: i. A physician diagnosis of stroke; OR ii. CT or MRI evidence of a prior stroke;
- •Fulfil ≥1 of the following 5 criteria (A-E): D. Undergoing major vascular surgery defined as all vascular surgeries (including any above foot amputation) with the exception of arteriovenous shunt, vein stripping procedures (varicose vein surgery), carotid endarterectomies, endovascular abdominal aortic aneurysm repair (EVAR); OR
- •Fulfil ≥1 of the following 5 criteria (A-E): E. Any 3 of 9 risk criteria: i. Undergoing major surgery defined as: intraperitoneal, intrathoracic, retroperitoneal, or major orthopaedic; ii. History of congestive heart failure defined as a physician diagnosis of a current or prior episode of congestive heart failure OR prior radiographic evidence of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary oedema; iii. History of a transient ischaemic attack; iv. Diabetes diagnosis and currently taking hypoglycemic agent; v. Age ≥70 years; vi. History of hypertension; vii. Serum creatinine >175 μmol/L (>2.0 mg/dl) based on the most recent values before randomisation; viii. History of smoking within 2 years of surgery; and ix. Undergoing emergent/urgent surgery, defined as surgery that a surgeon schedules to go to the operating room within 48 hours from an acute presentation to the hospital.
排除标准
- •Conduction abnormalities: A. Non-sinus rhythm on ECG; B. Sinoatrial or AV (2nd and 3d degree) blocks; C. Sick sinus syndrome; D. Long QT syndrome; E. Pacemaker dependent;
- •Inability to tolerate oral intake
- •Recent use of ivabradine (<1 month)
- •Known allergy or hypersensitivity to ivabradine
- •Low-risk surgical procedure based on individual physician's judgment
- •Investigator considers the patient unreliable regarding requirement for study compliance
- •Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
- •Previously enrolled in the PREVENT-MINS trial
- •Transplanted heart (or on waiting list)
- •Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
- •Resting heart rate <65 beats per minute on the day of surgery
- •Systolic blood pressure <90 mmHg on the day of surgery
- •Acute decompensated heart failure, cardiogenic shock, acute myocarditis
- •Acute coronary syndrome within 2 months before surgery
- •Stroke or transient cerebral ischaemia within 1 month before surgery
- •Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min)
结局指标
主要结局
Myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery
Myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery
次要结局
- Secondary outcomes at 30 days include: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; days alive and at home; stroke
- health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; intraoperative mean arterial pressure; intraoperative heart rate; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes.
研究者
prof. dr hab. Wojciech Szczeklik
Scientific
Uniwersytet Jagiellonski Collegium Medicum
研究点 (25)
Loading locations...
相似试验
尚未招募
Unknown
Role of medicine named ivabradine in tablet form to control changes in blood pressure and heart rate of patients undergoing surgery except heart surgery.CTRI/2017/11/010505Dr Anwesha Banerjee50
尚未招募
2 期
Ivabradine in the Prevention of Cardiac Injury in patients undergoing major Orthopaedic surgery.Cardiac injuryMortalityOrthopaedic SurgeryCardiovascular - Other cardiovascular diseasesInjuries and Accidents - FracturesACTRN12616001634460Department of Cardiology, Northern Hospital200
Enrolling By Invitation
2 期
Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery DiseaseNCT07268170Gødstrup Hospital350
进行中（未招募）
1 期
Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. There are drugs which may protect against cardiotoxic effects of anthracyclines, but they are untolerated due to hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which was approved for treatment of angina pectoris and heart failure. The aim of this study is to investigate protective effects of ivabradine in cancer patients undergoing anthracycline-based chemotherapy.Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung.EUCTR2019-000661-20-LTVilnius University Hospital Santaros klinikos150
进行中（未招募）
3 期
Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)Myocardial Injury After Noncardiac Surgery (MINS)Myocardial IschemiaNCT05279651Jagiellonian University2,146